The role of ixekizumab in non-radiographic axial spondyloarthritis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | San Koo, Bon | - |
dc.contributor.author | Kim, Tae-Hwan | - |
dc.date.accessioned | 2021-08-02T08:27:24Z | - |
dc.date.available | 2021-08-02T08:27:24Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1759-720X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/8061 | - |
dc.description.abstract | Among patients with axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA) is distinguished from ankylosing spondylitis (AS) by a lack of obvious radiographic changes in the sacroiliac joint. Tumor necrosis factor inhibitor (TNFi) has been used as a highly effective treatment in patients with AS and has shown good efficacy and safety in clinical trials in patients with nr-axSpA. As the pathophysiological mechanism for axSpA has started to become better recognized, various drugs other than TNFi, all of which are related to the interleukin-17 (IL-17) axis, are being evaluated in patients with axSpA. IL-17 inhibitors, such as secukinumab and ixekizumab, are effective drugs for patients with AS. A recent clinical trial reported that ixekizumab, a monoclonal antibody against IL-17A, was also effective in patients with nr-axSpA. In a COAST-X study, ixekizumab was superior to a placebo for improving signs and symptoms in patients with nr-axSpA at weeks 16 and 52. The adverse events were no different from those found in previous ixekizumab studies, and no new safety signals were identified. However, when considering several IL-17 inhibitors, it is necessary to obtain sufficient data to identify the exacerbation of extra-articular manifestation. In terms of effectiveness and safety, ixekizumab may be an appropriate alternative to TNFi in nr-axSpA patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SAGE Publications Inc. | - |
dc.title | The role of ixekizumab in non-radiographic axial spondyloarthritis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Tae-Hwan | - |
dc.identifier.doi | 10.1177/1759720X20986734 | - |
dc.identifier.scopusid | 2-s2.0-85099451321 | - |
dc.identifier.wosid | 000609877700001 | - |
dc.identifier.bibliographicCitation | Therapeutic Advances in Musculoskeletal Disease, v.13, pp.1 - 11 | - |
dc.relation.isPartOf | Therapeutic Advances in Musculoskeletal Disease | - |
dc.citation.title | Therapeutic Advances in Musculoskeletal Disease | - |
dc.citation.volume | 13 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | SOCIETY CLASSIFICATION CRITERIA | - |
dc.subject.keywordPlus | TUMOR-NECROSIS-FACTOR | - |
dc.subject.keywordPlus | ANKYLOSING-SPONDYLITIS | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | PSORIATIC-ARTHRITIS | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | HETERODIMERIC CYTOKINE | - |
dc.subject.keywordPlus | CLINICAL-TRIAL | - |
dc.subject.keywordPlus | POOLED DATA | - |
dc.subject.keywordAuthor | biologics | - |
dc.subject.keywordAuthor | IL-16 | - |
dc.subject.keywordAuthor | ixekizumab | - |
dc.subject.keywordAuthor | spondyloarthritis | - |
dc.subject.keywordAuthor | treatment | - |
dc.identifier.url | https://journals.sagepub.com/doi/10.1177/1759720X20986734 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.